About the company
Management team
Board of directors
Team expertise
Key advisers
Down syndrome
Alzheimer's disease
The Alzheimer's disease market
Diabetes
The Science behind Pharmasum
Protein kinases
DYRK1A - Role in different diseases
Proprietary inhibitors of DYRK1A
SBDD
Pipeline
News Releases
For Investor Relations, please contact:
Anders Fugelli
CEO Pharmasum Therapeutics
Phone: +47 924 81 432
Email: afugelli@pharmasum.com
